nach oben

Erschienen in:

01.09.2010 | Article

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes

verfasst von: M.-R. Taskinen, P. J. Barter, C. Ehnholm, D. R. Sullivan, K. Mann, J. Simes, J. D. Best, S. Hamwood, A. C. Keech, on behalf of the FIELD study investigators

Erschienen in: Diabetologia | Ausgabe 9/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The apolipoprotein B (ApoB):apolipoprotein A (ApoA)-I ratio may be a better indicator of cardiovascular disease (CVD) risk in people with type 2 diabetes than traditional lipid risk markers (LDL-cholesterol, HDL-cholesterol and triacylglycerol), but whether the ApoB:ApoA-I ratio should be used to indicate lipid-lowering therapy is still debated.

Methods

The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study randomised 9,795 patients with type 2 diabetes to fenofibrate (200 mg daily) or placebo and followed them up for a median of 5 years. We compared ApoB, ApoA-I, ApoAII and the ApoB:ApoA-I ratio with traditional lipid variables as predictors of CVD risk. We estimated the HR of the effect of 1 SD difference in baseline concentrations of lipids, apolipoproteins and respective ratios on the risk of CVD events and also used receiver operating characteristic curve analysis.

Results

In the placebo group, the variables best predicting CVD events were non-HDL-cholesterol:HDL-cholesterol, total cholesterol:HDL-cholesterol (HR 1.21, p < 0.001 for both), ApoB:ApoA-I (HR 1.20, p < 0.001), LDL-cholesterol:HDL-cholesterol (HR 1.17, p < 0.001), HDL-cholesterol (HR 0.84, p < 0.001) and ApoA-I (HR 0.85, p < 0.001). In the fenofibrate group, the first four predictors were very similar (but ApoB:ApoA-I was fourth), followed by non-HDL-cholesterol and ApoB. Lipid ratios and ApoB:ApoA-I performed better than any single lipid or apolipoprotein in predicting CVD risk.

Conclusions/interpretation

In patients with type 2 diabetes in the FIELD study, traditional lipid ratios were as strong as the ApoB:ApoA-I ratio in predicting CVD risk. The data provide little evidence for replacement of traditional lipids and their ratios with measures of ApoB, ApoA-I and their ratio.

Nur mit Berechtigung zugänglich

Taskinen MR (2005) Type 2 diabetes as a lipid disorder. Curr Mol Med 5:297–308CrossRefPubMed

Mooradian AD (2009) Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 5:150–159CrossRefPubMed

Cromwell WC, Otvos JD, Keyes MJ et al (2007) LDL particle number and risk of future cardiovascular disease in the Framingham offspring study—implications for LDL management. J Clin Lipidol 1:583–592CrossRefPubMed

Blake GJ, Otvos JD, Rifai N, Ridker PM (2002) Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in woman. Circulation 106:1930–1937CrossRefPubMed

Otvos JD, Collins D, Freedman DS et al (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113:1556–1563CrossRefPubMed

El Harchaoui K, van der Steeg WA, Stroes ES et al (2007) Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. J Am Coll Cardiol 49:547–553CrossRefPubMed

Sniderman A (2009) Targets for LDL-lowering therapy. Curr Opin Lipidol 20:282–287CrossRefPubMed

Lau JF, Smith DA (2009) Advanced lipoprotein testing: recommendations based on current evidence. Endocrinol Metab Clin North Am 38:1–31CrossRefPubMed

Contois JH, McConnell JP, Sethi AA et al (2009) Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 55:407–419CrossRefPubMed

10.

Barter PJ, Ballantyne CM, Carmena R et al (2006) Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259:247–258CrossRefPubMed

11.

Sniderman AD (2010) Apolipoprotein B, diabetes and medical consensus. Ann Clin Biochem 47:2–3CrossRefPubMed

12.

Miller M, Ginsberg HN, Schaefer EJ (2008) Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 101:1003–1008CrossRefPubMed

13.

Robinson JG, Wang S, Smith BJ, Jacobson TA (2009) Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 53:316–322CrossRefPubMed

14.

Rosenson RS (2009) Management of non-high-density lipoprotein abnormalities. Atherosclerosis 207:328–335CrossRefPubMed

15.

Lu W, Resnick HE, Jablonski KA et al (2003) Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 26:16–23CrossRefPubMed

16.

Jiang R, Schulze MB, Li T et al (2004) Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 27:1991–1997CrossRefPubMed

17.

Brunzell JD, Davidson M, Furberg CD, American Diabetes Association, American College of Cardiology Foundation et al (2008) Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31:811–822CrossRefPubMed

18.

No authors listed (2009) Executive summary: standards of medical care in diabetes—2009. Diabetes Care 32(Suppl 1):S6–S12

19.

Genest J, McPherson R, Frohlich J et al (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol 25:567–579PubMed

20.

Grundy SM, Cleeman JI, Merz CN, Coordinating Committee of the National Cholesterol Education Program et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 24:e149–e161CrossRefPubMed

21.

Blaha M, Blumenthal R, Brinton E, Jacobson T (2008) The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol 2:267–273CrossRef

22.

Chan DC, Watts GF (2006) Apolipoproteins as markers and managers of coronary risk. QJM 99:277–287CrossRefPubMed

23.

Denke MA (2005) Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 112:336–337CrossRef

24.

Kastelein JJ, van der Steeg WA, Holme I, NT Study Group, IDEAL Study Group et al (2008) Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117:3002–3009CrossRefPubMed

25.

Barter PJ, Rye KA (2006) The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 259:447–454CrossRefPubMed

26.

Thompson A, Danesh J (2006) Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 259:481–492CrossRefPubMed

27.

Lind L (2008) Apolipoprotein B/A1 and risk of cardiovascular disease. Lancet 372:185–186CrossRefPubMed

28.

Sulkes D, Brown BG, Krauss RM, Segrest JP, Sniderman AD, Roberts WC (2008) The editor’s roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk. Am J Cardiol 101:828–842CrossRefPubMed

29.

Charlton-Menys V, Durrington P (2006) Apolipoproteins AI and B as therapeutic targets. J Intern Med 259:462–472CrossRefPubMed

30.

Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026–2033CrossRefPubMed

31.

McQueen MJ, Hawken S, Wang X, INTERHEART study investigators et al (2008) Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet 372:224–233CrossRefPubMed

32.

Holme I, Cater NB, Faergeman O, Incremental Decrease in End-points Through Aggressive Lipid-Lowering (IDEAL) Study Group et al (2008) Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points Through Aggressive Lipid-lowering Trial (IDEAL). Ann Med 40:456–464CrossRefPubMed

33.

Sniderman AD (2007) Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go. Curr Opin Endocrinol Diabetes Obes 14:116–123PubMed

34.

Sniderman AD, Faraj M (2007) Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol 18:633–637CrossRefPubMed

35.

Davidson MH (2008) Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. Arterioscler Thromb Vasc Biol 28:1582–1583CrossRefPubMed

36.

Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000CrossRefPubMed

37.

Charlton-Menys V, Betteridge DJ, Colhoun H et al (2009) Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 52:218–225CrossRefPubMed

38.

FIELD study Investigators (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861CrossRef

39.

Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed

40.

van der Steeg WA, Boekholdt SM, Stein EA et al (2007) Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case–control analysis in EPIC-Norfolk. Ann Intern Med 146:640–648PubMed

41.

Ingelsson E, Schaefer EJ, Contois JH et al (2007) Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298:776–785CrossRefPubMed

42.

Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E (2009) Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 29:424–430CrossRefPubMed

43.

Scott R, O’Brien R, Fulcher G, Fenofibrate Intervention and Event Lowering in Diabetes Study Investigators et al (2009) Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32:493–498CrossRefPubMed

44.

ACCORD Study Group (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563–1574CrossRef

45.

Keeting GM, Croom KF (2007) Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 67:121–153CrossRef

46.

Després JP, Lemieux I, Salomon H, Delaval D (2002) Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. J Intern Med 251:490–499CrossRefPubMed

47.

Bard JM, Parra HJ, Camare R et al (1992) A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 41:498–503CrossRefPubMed

48.

Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA et al (2007) Apolipoprotein A-II is associated with risk of future coronary artery disease. Circulation 116:2029–2035CrossRefPubMed

49.

Langsted A, Freiberg JJ, Nordestgaard BG (2008) Fasting and nonfasting lipid levels influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 118:2047–2056CrossRefPubMed

50.

Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299–308CrossRefPubMed

Titel: Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
verfasst von: M.-R. Taskinen
P. J. Barter
C. Ehnholm
D. R. Sullivan
K. Mann
J. Simes
J. D. Best
S. Hamwood
A. C. Keech
on behalf of the FIELD study investigators
Publikationsdatum: 01.09.2010
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 9/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-010-1806-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes